viewFaron Pharmaceuticals Ltd

Faron Pharmaceuticals CEO details £12mln fundraise and new WHO coronavirus trial

Faron Pharmaceuticals Oy (LON:FARN) (NASDAQFIRSTNORTH:FARON) CEO Dr Markku Jalkanen speaks to Proactive London's Andrew Scott after announcing they're donating interferon beta-1a drug supplies to treat 2,000 patients taking part in a globally crucial coronavirus (COVID-19) study.

The World Health Organisation's Solidarity trial is assessing four drug options, including the Faron candidate, known as Traumakine.

Jalkanen also talks through their recent £12.18mln (€14mln) fundraise which will mainly be used to expand the current phase I/II MATINS trial of its Clevegen precision immunotherapy candidate.

Quick facts: Faron Pharmaceuticals Ltd

Price: 433.0001 GBX

Market: AIM
Market Cap: £202.64 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...


Market report: FTSE fragile Friday despite UK shoppers continuing to splurge...

Good morning, it’s a fragile Friday for the FTSE despite signs of some retail therapy as British retail sales continued to increase for the fourth consecutive month, boosted by spending on household goods and DIY, according to the ONS.  J Sainsbury PLC (LON:SBRY) is up after a...

3 hours, 14 minutes ago

2 min read